FDA Inspection 1120136 — Jubilant Cadista Pharmaceuticals

Jubilant Cadista Pharmaceuticals — FEI 3017221809

The FDA completed an inspection of Jubilant Cadista Pharmaceuticals on February 28, 2020 in Yardley, PA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
February 28, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yardley, PA (United States)

Citations

IDCFRDescription
145021 CFR 211.113(a)Procedures for non-sterile drug products
2153621 CFR 514.80(b)(1)Applicant did not submit/submitted late 3-Day Field Alert Report or wrong format
438921 CFR 211.198(a)Procedures to be written and followed